Sector News

Catalent snares yet another Belgian CDMO to boost fast-growing cell and gene therapy campus

May 8, 2021
Life sciences

Since purchasing cell and gene therapy CDMO MaSTherCell early last year, Catalent has been on an M&A tear in Belgium. With yet another deal, it’s bringing another local manufacturer—and a new factory—into the fold.

Catalent has acquired Promethera Biosciences’ cell therapy manufacturing subsidiary Hepatic Cell Therapy Support—the fourth company to join Catalent’s swiftly growing cell and gene therapy campus in Gosselies, Belgium. As part of the deal, Catalent will get its hands on HCTS’ 32,400-square-foot plant there, located right alongside the Delphi Genetics facility Catalent picked up earlier this year.

Catalent will use the plant for commercial-scale production of plasmid DNA (pDNA), which is an essential component for many biologics, including viral vectors, mRNA and cell therapies, the company said in a release. The new plant should provide an immediate boost to Catalent’s pDNA services, which came online with the recent purchase of plasmid DNA specialist Delphi, the company said.

Belgium’s Promethera, for its part, is “thrilled” to divest the HCTS plant to Catalent as it concentrates on its work in cell therapies for liver diseases, the company’s president Etienne Sokal, M.D., Ph.D., said in a statement.

Catalent’s latest Gosselies facility comes equipped with cleanrooms, warehouse space and process development and quality control labs. Catalent says it plans to “immediately” start building out the facility for pDNA manufacturing at up to 500 liters in scale. It will bring on more than 200 new employees at the plant over the next five years.

Catalent didn’t say how much it paid for HCTS, or whether the company’s current employees would stick around under the new ownership. The company didn’t immediately respond to Fierce Pharma’s request for comment.

The HCTS buy is Catalent’s third in Gosselies since it bought cell and gene CDMO MaSTherCell Global for $315 million last March. After that deal closed in 2020’s third quarter, Catalent took charge of about 240 MaSTherCell staffers, plus facilities in Belgium and Houston. Through the deal, Catalent also picked up a 60,000-square-foot commercial fill-finish plant in Gosselies that’s still under construction.

Then in October, Catalent said it would lay out $14 million for a 31,000-square-foot cell and gene therapy facility from Bone Therapeutics’ Skeletal Cell Therapy Support subsidiary. At the time, Catalent said it would pair the two sites in Gosselies to create a cell therapy “center of excellence” by the end of 2021.

The CDMO has shown no signs of slowing down since then. Catalent in February locked up a deal to acquire pDNA specialist Delphi, taking over the company’s 17,000-square-foot Gosselies headquarters and manufacturing plant.

Catalent also got its hands on Delphi’s STABY technology, an antibiotic-free selection system used to make plasmids and proteins in E. coli, which it planned to transfer over to its Rockville plant, Colleen Floreck, vice president of global marketing and strategy at Catalent Cell and Gene Therapy, told Fierce Pharma at the time.

by Fraiser Kansteiner

Source: fiercepharma.com

comments closed

Related News

January 23, 2022

UCB to acquire Zogenix

Life sciences

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

January 23, 2022

argenx announces VYVGART™ approval in Japan for the treatment of generalized myasthenia gravis

Life sciences

argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved VYVGART™ (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who do not have sufficient response to steroids or non-steroidal immunosuppressive therapies (ISTs).

January 23, 2022

GlaxoSmithKline rejects Unilever’s $68B consumer health buyout offer, but a bigger bid is brewing

Life sciences

GSK has rejected three offers from Unilever to buy GSK’s consumer health unit, the company said Saturday. The latest offer from the fellow U.K. consumer goods giant, received Dec. 20 for a total value of 50 billion pounds ($68 billion), “fundamentally undervalued” the business and its prospects, GSK said.

Send this to a friend